Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation
周达标 Zhou Dabiao
1
,
Ning Ding
2
,
Z. L. Du
1
,
张志荣 Zhang Zhirong
2
,
Hong Wang
2
,
XING-CHUAN WEI
1
,
Allan H. Conney
1
,
Kun Zhang
1
,
Xi Zheng
1
Publication type: Journal Article
Publication date: 2014-07-14
scimago Q2
wos Q2
SJR: 0.841
CiteScore: 8.5
Impact factor: 3.5
ISSN: 17912997, 17913004
PubMed ID:
25060817
Biochemistry
Cancer Research
Oncology
Molecular Biology
Genetics
Molecular Medicine
Abstract
The androgen receptor (AR) has a critical role in prostate cancer development and progression. Several curcumin analogues (A10, B10, C10, E10 and F10) with different linker groups were investigated for their effects in human prostate cancer CWR‑22Rv1 and LNCaP cell lines. The ability of these compounds to inhibit testosterone (TT)‑ or dihydrotestosterone (DHT)‑induced AR activity was determined by an AR‑linked luciferase assay and by TT‑ or DHT‑induced expression of prostate specific antigen. Compounds F10 and E10 had stronger inhibitory effects on the growth of cultured CWR‑22Rv1 and LNCaP cell lines, and they also had enhanced stimulatory effects on apoptosis compared with curcumin and other curcumin analogues (A10, B10, C10) in CWR‑22Rv1 cells. E10 and F10 were more potent inhibitors of AR activity than curcumin, A10 and B10. The higher activities of E10 and F10 may be correlated with a heteroatom linker. The results indicate that one of the potential mechanisms for the anticancer effect of the curcumin analogues was inhibition of AR pathways in human prostate cancer cells.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
|
|
|
Frontiers in Pharmacology
4 publications, 11.43%
|
|
|
Cancers
2 publications, 5.71%
|
|
|
Interventional Medicine and Applied Science
1 publication, 2.86%
|
|
|
International Journal of Oncology
1 publication, 2.86%
|
|
|
Biomedicines
1 publication, 2.86%
|
|
|
Structural Chemistry
1 publication, 2.86%
|
|
|
Molecular Biology Reports
1 publication, 2.86%
|
|
|
PLoS ONE
1 publication, 2.86%
|
|
|
Journal of Herbal Medicine
1 publication, 2.86%
|
|
|
Experimental Cell Research
1 publication, 2.86%
|
|
|
Seminars in Cancer Biology
1 publication, 2.86%
|
|
|
Pharmacological Research
1 publication, 2.86%
|
|
|
Journal of Traditional and Complementary Medicine
1 publication, 2.86%
|
|
|
Gene
1 publication, 2.86%
|
|
|
Journal of Molecular Structure
1 publication, 2.86%
|
|
|
Molecular Carcinogenesis
1 publication, 2.86%
|
|
|
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
1 publication, 2.86%
|
|
|
Journal of Agricultural and Food Chemistry
1 publication, 2.86%
|
|
|
Chemical Research in Toxicology
1 publication, 2.86%
|
|
|
Current Bioactive Compounds
1 publication, 2.86%
|
|
|
Asian Pacific Journal of Cancer Prevention
1 publication, 2.86%
|
|
|
Oxidative Medicine and Cellular Longevity
1 publication, 2.86%
|
|
|
Phytotherapy Research
1 publication, 2.86%
|
|
|
Urologia
1 publication, 2.86%
|
|
|
Medicinal Research Reviews
1 publication, 2.86%
|
|
|
Biochemical and Biophysical Research Communications
1 publication, 2.86%
|
|
|
Heliyon
1 publication, 2.86%
|
|
|
Russian Chemical Reviews
1 publication, 2.86%
|
|
|
1
2
3
4
|
Publishers
|
2
4
6
8
10
|
|
|
Elsevier
10 publications, 28.57%
|
|
|
Frontiers Media S.A.
4 publications, 11.43%
|
|
|
Wiley
4 publications, 11.43%
|
|
|
MDPI
3 publications, 8.57%
|
|
|
Springer Nature
3 publications, 8.57%
|
|
|
American Chemical Society (ACS)
2 publications, 5.71%
|
|
|
Akademiai Kiado
1 publication, 2.86%
|
|
|
Spandidos Publications
1 publication, 2.86%
|
|
|
Public Library of Science (PLoS)
1 publication, 2.86%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 2.86%
|
|
|
Asian Pacific Organization for Cancer Prevention
1 publication, 2.86%
|
|
|
Hindawi Limited
1 publication, 2.86%
|
|
|
SAGE
1 publication, 2.86%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 2.86%
|
|
|
2
4
6
8
10
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
35
Total citations:
35
Citations from 2024:
6
(17.14%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Zhou Dabiao 周. et al. Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation // Molecular Medicine Reports. 2014. Vol. 10. No. 3. pp. 1315-1322.
GOST all authors (up to 50)
Copy
Zhou Dabiao 周., Ding N., Du Z. L., Zhang Zhirong 张., Wang H., WEI X., Conney A., Zhang K., Zheng X. Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation // Molecular Medicine Reports. 2014. Vol. 10. No. 3. pp. 1315-1322.
Cite this
RIS
Copy
TY - JOUR
DO - 10.3892/mmr.2014.2380
UR - https://doi.org/10.3892/mmr.2014.2380
TI - Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation
T2 - Molecular Medicine Reports
AU - Zhou Dabiao, 周达标
AU - Ding, Ning
AU - Du, Z. L.
AU - Zhang Zhirong, 张志荣
AU - Wang, Hong
AU - WEI, XING-CHUAN
AU - Conney, Allan H.
AU - Zhang, Kun
AU - Zheng, Xi
PY - 2014
DA - 2014/07/14
PB - Spandidos Publications
SP - 1315-1322
IS - 3
VL - 10
PMID - 25060817
SN - 1791-2997
SN - 1791-3004
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2014_Zhou Dabiao,
author = {周达标 Zhou Dabiao and Ning Ding and Z. L. Du and 张志荣 Zhang Zhirong and Hong Wang and XING-CHUAN WEI and Allan H. Conney and Kun Zhang and Xi Zheng},
title = {Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation},
journal = {Molecular Medicine Reports},
year = {2014},
volume = {10},
publisher = {Spandidos Publications},
month = {jul},
url = {https://doi.org/10.3892/mmr.2014.2380},
number = {3},
pages = {1315--1322},
doi = {10.3892/mmr.2014.2380}
}
Cite this
MLA
Copy
Zhou Dabiao, 周达标, et al. “Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation.” Molecular Medicine Reports, vol. 10, no. 3, Jul. 2014, pp. 1315-1322. https://doi.org/10.3892/mmr.2014.2380.